Duloxetine: clinical pharmacokinetics and drug interactions.
about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Placental transfer of antidepressant medications: implications for postnatal adaptation syndromeDuloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory studyDrug-drug interactions between warfarin and psychotropics: updated review of the literature.Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.Duloxetine in the management of chronic musculoskeletal painDuloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groupsDrug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirRapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.Clinically significant drug interactions with newer antidepressants.A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.Duloxetine: a review of its use in the management of major depressive disorder in older adults.Clinically significant drug interactions with atypical antipsychotics.Pharmacokinetic considerations for therapies used to treat interstitial cystitis.Pharmacokinetics of antidepressants in patients with hepatic impairment.Smoking and mental illness. An update for psychiatrists.Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature.Psychopharmacology and Bariatric Surgery.Alleviation of pain in painful diabetic neuropathy.Comprehensive Duloxetine Analysis in a Fatal Overdose.Neuropathic pain: a narrative review of etiology, assessment, diagnosis, and treatment for primary care providers.Enhancement of nootropic effect of duloxetine and bupropion by caffeine in mice.Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.The effect of single oral doses of duloxetine, reboxetine, and midodrine on the urethral pressure in healthy female subjects, using urethral pressure reflectometry.Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects.Parkinsonism secondary to duloxetine use: a case report.
P2860
Q26741187-87F35B87-E04A-4661-BC6D-AE955DBD10E4Q26999391-A9FA932C-9A4B-4660-A68D-1E06BB7730A5Q28483370-659928E9-1E79-4EB6-8B60-46BAF451489FQ34432843-A078CA30-9D12-4E96-BF1B-3776C4BA086CQ35111188-2A295271-A1B1-4549-B6C3-39017F4B0D28Q36071024-2E85F143-74B8-485A-B700-F8DC6068E334Q36395440-597311B6-19FD-4E3A-9F16-7563875CAD45Q36438920-1E72372E-AB65-4B6D-BC3D-DD2A1FF6EE62Q37365650-99AB6D21-F0EC-4F1C-938E-BB94F27BEA0FQ37968621-96183F79-31BC-4E2B-A452-C01E20A23FB1Q38020236-AE789D6B-4DEE-455C-8BCF-8CF70E3F86D3Q38067355-228F6DF1-FBC1-4497-8AAB-8364183E8762Q38156416-3D15BEA0-05DB-4994-805E-C0C071610B2AQ38195318-5A09E832-33A9-4A74-B8B8-4AE07ED845AAQ38253564-D82406E0-1A49-4039-B7AB-BC381E52E39FQ38290164-BBD548F3-9EE0-431A-8C30-789A70C9BAA1Q38313416-A5D1F64A-21D2-4AD3-97FD-BC2C4DB3D971Q38580433-7F1C8095-4140-43CB-BD9A-BCB1861350DBQ38826512-0F18A5F4-EC65-4B88-A592-FE8EDB630C64Q38932489-5D12F39F-9F0B-4331-A177-F9AA433D610DQ39250516-F716F3A7-E0A3-41B2-91EE-25123FDBEE04Q39257915-16AACAE3-DD68-4F3D-904C-19178F5C66CEQ40901122-152B5CC7-E8D8-4FB3-ABE5-B897A8CF1284Q41984338-D5B0F1F6-B4FF-40F1-B512-546646079460Q42145602-70F15B27-9D10-4A44-AF8A-39C30B88E705Q47097473-FB4966A1-ACFD-4172-9F74-B5F6BBC37E96Q47790460-93826695-1A13-4606-AF22-9E79B54A3E94Q47937029-89207D20-3002-4DCC-BC4A-690737B2AD2FQ53185668-3BA7E59F-334E-4423-8020-4675F599C365Q55112412-5C425D91-36DD-49E5-B43F-8913F3883778
P2860
Duloxetine: clinical pharmacokinetics and drug interactions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Duloxetine: clinical pharmacokinetics and drug interactions.
@en
Duloxetine: clinical pharmacokinetics and drug interactions.
@nl
type
label
Duloxetine: clinical pharmacokinetics and drug interactions.
@en
Duloxetine: clinical pharmacokinetics and drug interactions.
@nl
altLabel
Duloxetine: clinical pharmacokinetics and drug interactions
@en
prefLabel
Duloxetine: clinical pharmacokinetics and drug interactions.
@en
Duloxetine: clinical pharmacokinetics and drug interactions.
@nl
P2093
P2860
P1476
Duloxetine: clinical pharmacokinetics and drug interactions.
@en
P2093
Evelyn Lobo
Jill Chappell
Mary Pat Knadler
Richard Bergstrom
P2860
P304
P356
10.2165/11539240-000000000-00000
P407
P577
2011-05-01T00:00:00Z